9:15 AM - 9:30 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
ISOThrive is a microbiome inspired therapeutics company that has developed a novel patented and patents-pending treatment targeting gastroesophageal reflux disease (a.k.a. GERD or chronic acid reflux). Our unique carbohydrate is designed to restore the normal localized microbiome at the lower esophageal sphincter, and thereby stop acid reflux at the root cause. In addition, there is growing evidence that suggests that the abnormal microbiome that exists with GERD, and the chronic inflammation that results, may be the cause of the progression of GERD to Barrett’s Esophagus and ultimately to cancer of the esophagus. By restoring the normal local microbiome, ISOThrive may also prevent esophageal cancer. ISOThrive’s microbiome inspired platform addresses many other indications including IBS and colorectal cancer.
Company Type:
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
ISOThrive (ISOT 101)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided